Reference information only. Always consult a qualified healthcare professional.
MPMediPriceHubMedicine price reference
PRODUCT INFORMATION

Pazinib 400mg Tablet

Pazopanib (400mg)

Pazinib 400mg Tablet
Reference priceINR ₹4,031.25Original source price: INR 4,031.25. Converted estimates are available by currency selection.
BrandHetero Healthcare Ltd
ManufacturerHetero Healthcare Ltd
Prescription requiredYes

Description

Pazinib 400mg Tablet is a protein kinase inhibitor used in the treatment of kidney cancer and soft tissue sarcoma.

Benefits

In Kidney cancer Pazinib 400mg Tablet is used to treat kidney cancer and its associated symptoms such as blood in the urine, unexplained low back pain or weight loss, fatigue, loss of appetite, etc. It stops cancer growth and prevents multiplication of cancer cells. This restricts the advancement of cancer to other unaffected regions. You need to follow your doctor’s instructions very carefully to recover. In Soft tissue sarcoma Soft tissue sarcoma is a type of sarcoma that develops in tissues such as bone and muscles. Pazinib 400mg Tablet kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. Follow your doctor’s instructions carefully and let your doctor know if any of the side effects bother you.

How to Use

Take this medicine in the dose and duration as advised by your doctor.

Specification

Take this medicine in the dose and duration as advised by your doctor.

Side Effects

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them Common side effects of Pazinib Headache Nausea Vomiting Musculoskeletal (bone, muscle or joint) pain Fatigue Change in color of hair Diarrhea High blood pressure Decreased appetite Weight loss Taste change Abnormal skin pigmentation Hair discoloration Tumor pain Breathlessness

This information is for reference only. Consult a qualified healthcare professional before using any medicine.